AURA · Aura Biosciences, Inc. · Executive Compensation
Market Cap
$725.93M
Shares
103.70M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Elisabet de los Pinos | President, Chief Executive Officer and Director | $6,816,256 |
| Cadmus C. Rich | Chief Medical Officer and Head of Research & Development | $2,398,624 |
| Julie B. Feder | Chief Financial Officer | $2,339,855 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Elisabet de los Pinos | President, Chief Executive Officer and Director | $1,094,900 |
| Cadmus C. Rich | Chief Medical Officer and Head of Research & Development | $632,366 |
| Julie B. Feder | Chief Financial Officer | $552,342 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Anthony Gibney | Chief Financial and Business Officer | Resigned | 2026-08-11 |
| Susan Abu-Absi | Chief Operating Officer | Appointed | 2026-08-11 |
| Jeremy Bender, Ph.D., M.B.A. | Class II director | Appointed | 2026-07-08 |
| Natalie Holles | Class I director | Appointed | 2026-05-04 |
| Natalie Holles | Chief Executive Officer and President | Appointed | 2026-05-04 |
| Anthony Gibney | Chief Financial and Business Officer | Appointed | 2025-05-15 |
| Teresa Marie Bitetti | Class II director | Appointed | 2025-04-02 |
| Julie Feder | Chief Financial Officer | Resigned | 2024-09-27 |